BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29777663)

  • 1. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
    Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
    Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
    Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Female sexual function in women using LARC methods.
    Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
    Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A.
    Rowe P; Farley T; Peregoudov A; Piaggio G; Boccard S; Landoulsi S; Meirik O;
    Contraception; 2016 Jun; 93(6):498-506. PubMed ID: 26916172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of intrauterine devices among young women: a systematic review.
    Jatlaoui TC; Riley HEM; Curtis KM
    Contraception; 2017 Jan; 95(1):17-39. PubMed ID: 27771475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review.
    Sanders JN; Turok DK; Gawron LM; Law A; Wen L; Lynen R
    Am J Obstet Gynecol; 2017 Jun; 216(6):590.e1-590.e8. PubMed ID: 28188772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
    Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
    Moray KV; Chaurasia H; Sachin O; Joshi B
    Reprod Health; 2021 Jan; 18(1):4. PubMed ID: 33407632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Obesity Influence Body Mass Index Changes in Nulliparous Adolescent Users of Long-Acting Reversible Contraceptives?
    Scott N; Silver EJ; Dodson NA; Coupey SM
    J Pediatr Adolesc Gynecol; 2021 Dec; 34(6):815-820. PubMed ID: 34389461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.